Pliant Therapeutics Inc.
12/16/2025 | Press release | Distributed by Public on 12/16/2025 16:06
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 10, 2025, Pliant Therapeutics, Inc.'s (the "Company") Board of Directors (the "Board") appointed Minnie Kuo as Chief Operating Officer, effective immediately.
Ms. Kuo, age 45, joined the Company in September 2023 as Chief Development Officer and served in such position until her appointment as Chief Operating Officer. She is an experienced biotechnology and pharmaceutical executive and brings more than 20 years of multinational clinical development experience across various therapeutic areas including respiratory, oncology, neurodegenerative, inflammatory, and infectious diseases. Ms. Kuo joined Pliant from Vir Biotechnology where she held roles of increasing responsibilities, most recently serving as Senior Vice President of Translational and Clinical Development Operations. In that role, she led business operations, clinical operations, and organizational planning across the entire clinical portfolio. Prior to Vir, Ms. Kuo held senior clinical operations roles at Nektar Therapeutics and Gilead Sciences. At Gilead, she oversaw the strategic direction of multiple compounds and indications within the company's inflammation and hepatic portfolios. Earlier in her career, Ms. Kuo held global project management and clinical study management roles at Roche/Genentech and at clinical research organizations including ICON and PharmaNet. Ms. Kuo received her Bachelor of Arts from the University of California, San Diego, and a Masters of Science from the University of San Francisco.
Ms. Kuo was not provided with any additional compensation at the time of her appointment as Chief Operating Officer.
There is no family relationship between Ms. Kuo and any other person that would require disclosure under Item 401(d) of Regulation S-K. Ms. Kuo is also not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.
Pliant Therapeutics Inc. published this content on December 16, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 16, 2025 at 22:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]